You might be interested in
Health & Biotech
SomnoMed taps tech for new board hires, posts full-year profit
Health & Biotech
Osprey gets European tick of approval for latest device
Health & Biotech
Health & Biotech
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.
In this episode Tim interviews Mike McCormick, president & CEO of Osprey Medical (ASX:OSP).
Osprey is focused on improving outcomes in chronic kidney disease patients by reducing contrast-induced acute kidney injury caused by widely used contrast dyes.
The company was featured in a Stockhead article last year looking at its Australia and New Zealand distribution deal with Regional Health Care Group.
So tune in below to hear about all things Osprey Medical.
On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.
Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!